Ultragenyx Pharmaceutical Inc. (RARE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673.00M, up 20.2% from the prior year. The company ran a net loss, with a net margin of -85.4%. It held $1.53B in total assets against $1.60B in total liabilities.
Key ratios (FY2025)
-79.5%
Operating margin
-85.4%
Net margin
+20.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.00M | $560.00M | $434.00M | $363.33M | $351.41M | $271.03M | $103.71M | $51.49M | $2.61M | $133.0K |
| Cost of Revenue | — | — | — | — | — | — | — | $1.15M | $1.0K | — |
| Operating Income | -$535.00M | -$536.00M | -$569.00M | -$648.92M | -$381.74M | -$330.12M | -$424.17M | -$371.37M | -$328.94M | -$248.01M |
| Net Income | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -$454.02M | -$186.57M | -$402.73M | -$197.61M | -$302.14M | -$245.87M |
| EPS (Diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | — | — | — | — |
| Total Assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B | $1.76B | $1.14B | $719.56M | $490.75M | $540.63M |
| Total Liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.84M | $605.18M | $481.73M | $110.65M | $107.30M | $66.65M |
| Shareholders' Equity | -$80.00M | $255.00M | $275.00M | $352.00M | $922.56M | $1.15B | $653.76M | $608.91M | $383.45M | $473.97M |
| Cash & Equivalents | $421.00M | $174.00M | $214.00M | $132.94M | $307.58M | $713.53M | $433.58M | $113.43M | $100.49M | $161.12M |
| Operating Cash Flow | -$466.00M | -$414.00M | -$475.00M | -$380.46M | -$338.69M | -$132.22M | -$345.38M | -$290.57M | -$253.84M | -$160.97M |
| Capital Expenditures | $6.00M | $7.00M | $44.00M | $116.12M | $73.09M | $43.91M | $24.83M | $4.08M | $2.79M | $10.19M |
| Shares Outstanding | 96.60M | 92.50M | 82.32M | 70.20M | 69.34M | 66.82M | 57.84M | 50.86M | 44.17M | 41.24M |